Business Wire

Boomi Named a Leader and Secures Top Score in Strategy Category in Latest iPaaS Report by Independent Research Firm

27.8.2025 18:30:00 EEST | Business Wire | Press release

Share

Boomi™, the leader in AI-driven automation, today announced it has been named a Leader in The Forrester Wave™: Integration Platform As A Service, Q3 2025. The report evaluated the 10 most significant iPaaS vendors, and Boomi achieved the highest score in thestrategy category among all evaluated providers.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250826324359/en/

Boomi Named a Leader and Secures Top Score in Strategy Category in Latest iPaaS Report by Independent Research Firm

The report states that Boomi has reoriented with an “intense focus on AI and APIs,” “receives strong feedback from its partners,” and maintains “clear investment priorities.” Reference customers were impressed by the company’s level of investment in the product and its vision for the future, and look forward to seeing Boomi deliver on its AI roadmap.

“We’re honored to be named a Leader in the Forrester Wave — and especially proud to receive the top score in the strategy category,” said Ed Macosky, Chief Product and Technology Officer at Boomi. “For us, this recognition validates our belief that integration is foundational to delivering meaningful, production-grade AI. We're investing heavily to help our customers build intelligent, scalable, and future-ready enterprises through agentic transformation.”

The Forrester report states: “Boomi is a great choice for customers who need a well-rounded iPaaS for broad integration use cases and who see integration as foundational to implementing their AI and automation strategy.”1

The Boomi Enterprise Platform enables organizations to unify data, applications, and systems with speed and simplicity — unlocking new levels of agility, automation, and intelligence. In this Forrester Wave, Boomi received the highest scores in 10 criteria, including vision, innovation, roadmap, and supporting services and offerings, and was cited for its above-par ease of use through AI assistants.

Boomi’s Key Highlights from the Forrester Wave™: iPaaS, Q3 2025

  • Strategic Focus on AI and APIs:
    Boomi has reoriented with an intense focus on AI and APIs in a bid to pull ahead of the market, including the acquisition of managed file transfer vendor Thru during the evaluation period.
  • Vision:
    Boomi’s vision centers on delivering a unified platform that accelerates time to market, reduces costs, and improves customer experiences at scale through AI-driven automation.
  • Roadmap:
    Boomi’s roadmap emphasizes tools for building AI agents, while continuing to invest in data integration, event streaming, and expanding connector support.
  • Strong Partner Feedback:
    Boomi received praise from partners, with one prominent global systems integrator (GSI) praising Boomi as “the best iPaaS vendor it works with.”
  • Strategic Execution:
    Boomi maintains innovation momentum through a dedicated strategy team, targeted investment priorities, and a disciplined approach to strategic acquisitions.
  • Ease of Use and Robust SLA:
    Boomi offers excellent tools for building, testing, and governing AI agents and is backed by the highest publicly disclosed SLA among all evaluated vendors — at least 99.99% uptime with financial credits when it is breached from 10% to 100%.
  • Customer-Centric Support Model:
    Experienced technical consultants embedded in the customer success organization provide hands-on support to enterprise customers.

To access the full Forrester Wave report, visit https://boomi.com/content/report/forrester-wave

Additional Resources

Forrester does not endorse any company, product, brand, or service included in its research publications and does not advise any person to select the products or services of any company or brand based on the ratings included in such publications. Information is based on the best available resources. Opinions reflect judgment at the time and are subject to change. For more information, read about Forrester’s objectivity here.

About Boomi
Boomi, the leader in AI-driven automation, enables organizations worldwide to connect everything, automate processes, and accelerate outcomes. The Boomi Enterprise Platform — including Boomi Agentstudio — unifies integration and automation along with data, API, and AI agent management, in a single, comprehensive solution. Trusted by over 25,000 customers and supported by a network of 800+ partners, Boomi is driving agentic transformation — helping enterprises of all sizes achieve agility, efficiency, and innovation at scale. Discover more at boomi.com.

© 2025 Boomi, LP. Boomi, the ‘B’ logo, and Boomiverse are trademarks of Boomi, LP or its subsidiaries or affiliates. All rights reserved. Other names or marks may be the trademarks of their respective owners.

___________________________

1 The Forrester Wave™: Integration Platform As A Service, Q3 2025

View source version on businesswire.com: https://www.businesswire.com/news/home/20250826324359/en/

Contacts

Media Relations Contact:
Kristen Walker
Boomi Global Corporate Communications
kristen.walker@boomi.com

Analyst Relations Contact:
Kate Mauser
Boomi Analyst Relations
kate.mauser@boomi.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release

International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release

Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye